Key result
Oral magnesium citrate, oxide, and sulfate supplementation for 24 weeks did not significantly change carotid-to-femoral pulse wave velocity or blood pressure compared with placebo.
Why the study?
Magnesium supplements may benefit arterial stiffness, but head-to-head comparisons between various magnesium formulations regarding arterial stiffness and blood pressure had not been performed.
Does magnesium supplementation (citrate, oxide, or sulfate) improve arterial stiffness in overweight and slightly obese subjects?
RCT (n=164)
Double-blind
randomized
Does magnesium supplementation (citrate, oxide, or sulfate) improve arterial stiffness in overweight and slightly obese subjects?
Oral magnesium supplementation (citrate, oxide, or sulfate) at 450 mg/d for 24 weeks does not improve arterial stiffness or blood pressure in overweight and slightly obese individuals.
Magnesium not indicated for arterial stiffness in overweight adults; challenges observational associations with vascular benefit.
Background Magnesium supplements may have beneficial effects on arterial stiffness. Yet, to our knowledge, no head-to-head comparison between various magnesium formulations in terms of effects on arterial stiffness has been performed. We assessed the effects of magnesium citrate supplementation on arterial stiffness and blood pressure and explored whether other formulations of magnesium have similar effects. Methods and Results In this randomized trial, subjects who were overweight and slightly obese received either magnesium citrate, magnesium oxide, magnesium sulfate, or placebo for 24 weeks. The total daily dose of magnesium was 450 mg/d. The primary outcome was carotid-to-femoral pulse wave velocity, which is the gold standard method for measuring arterial stiffness. Secondary outcomes included blood pressure and plasma and urine magnesium. Overall, 164 participants (mean±SD age, 63.2±6.8 years; 104 [63.4%] women) were included. In the intention-to-treat analysis, neither magnesium citrate nor the other formulations had an effect on carotid-to-femoral pulse wave velocity or blood pressure at 24 weeks compared with placebo. Magnesium citrate increased plasma (+0.04 mmol/L; 95% CI, +0.02 to +0.06 mmol/L) and urine magnesium (+3.12 mmol/24 h; 95% CI, +2.23 to +4.01 mmol/24 h) compared with placebo. Effects on plasma magnesium were similar among the magnesium supplementation groups, but magnesium citrate led to a more pronounced increase in 24-hour urinary magnesium excretion than magnesium oxide or magnesium sulfate. One serious adverse event was reported, which was considered unrelated to the study treatment. Conclusions Oral magnesium citrate supplementation for 24 weeks did not significantly change arterial stiffness or blood pressure. Magnesium oxide and magnesium sulfate had similar nonsignificant effects. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03632590.
No takes yet. Share an insight, caveat, or question.
A 2022 study conducted an RCT in overweight and slightly obese (n=164). Magnesium citrate, magnesium oxide, and magnesium sulfate vs. placebo was evaluated on carotid-to-femoral pulse wave velocity. Oral magnesium citrate, oxide, and sulfate supplementation for 24 weeks did not significantly change carotid-to-femoral pulse wave velocity or blood pressure compared with placebo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: